From Wikipedia, the free encyclopedia
Chemical compound
Simmerafil
[1] (TPN171H) is a selective
PDE5 inhibitor
[2] in development for the treatment of
erectile dysfunction
[3] and
pulmonary hypertension.
[4]
-
^ Odilov, Abdullajon; Liu, Yin; Hu, Tianwen; Jiang, Xiangrui; Suo, Jin; Tian, Guanghui; Yang, Feipu; Shen, Jingshan (19 November 2021).
"Facile and Cost-Effective Route for the Synthesis of Simmerafil". Organic Process Research & Development. 25 (11): 2432–2437.
doi:
10.1021/acs.oprd.1c00184.
ISSN
1083-6160.
S2CID
244619662.
-
^ Qian, Hongjie; Chen, Qian; Liang, Liyu; Zou, Yang; Pu, Huahua; Xin, Liang; Song, Rong; Li, Tingting; Zhu, Huijuan; Wang, Yu; Tian, Guanghui; Shen, Jingshan; Jiang, Hualiang; Yu, Chen; Wang, Zhen; Jia, Jingying (2021).
"A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects". Drug Design, Development and Therapy. 15: 2947–2959.
doi:
10.2147/DDDT.S308610.
ISSN
1177-8881.
PMC
8273902.
PMID
34262260.
-
^
"Efficacy and Safety Study of TPN171H Tablets in Erectile Dysfunction". www.clinicaltrials.gov. CTG Labs. Retrieved 9 November 2023.
-
^ Zhao, Congke; Hu, Liqing; He, Xiangrong; Li, Lijun; Yin, Minghui; Tettey, Abraham Terkpertey; Wang, Yu; Shen, Jingshan; Tang, Siyuan; Wu, Chunhui; Li, Qianbin; Wang, Zhen; Li, Xiaohui (1 August 2022).
"TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats". Vascular Pharmacology. 145: 107017.
doi:
10.1016/j.vph.2022.107017.
ISSN
1537-1891.
PMID
35680060.
S2CID
249490064.